Trevi Therapeutics (TRVI) Competitors $6.20 +0.25 (+4.20%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$5.75 -0.45 (-7.24%) As of 04:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI vs. AMRX, MLTX, TWST, HCM, MIRM, VCEL, BHC, BHVN, TARS, and GMTXShould you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Amneal Pharmaceuticals (AMRX), MoonLake Immunotherapeutics (MLTX), Twist Bioscience (TWST), HUTCHMED (HCM), Mirum Pharmaceuticals (MIRM), Vericel (VCEL), Bausch Health Companies (BHC), Biohaven (BHVN), Tarsus Pharmaceuticals (TARS), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Trevi Therapeutics vs. Amneal Pharmaceuticals MoonLake Immunotherapeutics Twist Bioscience HUTCHMED Mirum Pharmaceuticals Vericel Bausch Health Companies Biohaven Tarsus Pharmaceuticals Gemini Therapeutics Amneal Pharmaceuticals (NASDAQ:AMRX) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership. Do insiders and institutionals have more ownership in AMRX or TRVI? 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 24.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer AMRX or TRVI? Amneal Pharmaceuticals presently has a consensus target price of $10.80, indicating a potential upside of 50.63%. Trevi Therapeutics has a consensus target price of $17.56, indicating a potential upside of 183.27%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.30 Which has stronger earnings & valuation, AMRX or TRVI? Trevi Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.79B0.80-$83.99M-$0.38-18.87Trevi TherapeuticsN/AN/A-$29.07M-$0.47-13.19 Does the MarketBeat Community believe in AMRX or TRVI? Trevi Therapeutics received 88 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 94.74% of users gave Amneal Pharmaceuticals an outperform vote while only 67.95% of users gave Trevi Therapeutics an outperform vote. CompanyUnderperformOutperformAmneal PharmaceuticalsOutperform Votes1894.74% Underperform Votes15.26%Trevi TherapeuticsOutperform Votes10667.95% Underperform Votes5032.05% Which has more volatility and risk, AMRX or TRVI? Amneal Pharmaceuticals has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Does the media favor AMRX or TRVI? In the previous week, Trevi Therapeutics had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 11 mentions for Trevi Therapeutics and 8 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.15 beat Trevi Therapeutics' score of 0.62 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AMRX or TRVI more profitable? Trevi Therapeutics has a net margin of 0.00% compared to Amneal Pharmaceuticals' net margin of -6.88%. Trevi Therapeutics' return on equity of -63.31% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals-6.88% -346.26% 4.85% Trevi Therapeutics N/A -63.31%-57.06% SummaryTrevi Therapeutics beats Amneal Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Remove Ads Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition Export to ExcelMetricTrevi TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$599.43M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-14.096.7921.6617.82Price / SalesN/A225.97373.3994.61Price / CashN/A65.6738.1534.64Price / Book4.815.866.474.00Net Income-$29.07M$141.86M$3.20B$247.23M7 Day Performance14.81%4.50%2.86%1.45%1 Month Performance-8.15%-12.65%-8.56%-6.24%1 Year Performance132.65%-11.06%10.58%0.60% Trevi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics3.3949 of 5 stars$6.20+4.2%$17.56+183.3%+120.6%$599.43MN/A-14.0920AMRXAmneal Pharmaceuticals3.2294 of 5 stars$7.21-2.3%$10.80+49.8%+29.4%$2.23B$2.79B-10.607,600Short Interest ↑Positive NewsMLTXMoonLake Immunotherapeutics2.162 of 5 stars$34.78-6.5%$80.50+131.5%-15.7%$2.23BN/A-26.962Positive NewsGap UpHigh Trading VolumeTWSTTwist Bioscience3.4736 of 5 stars$36.99+2.2%$54.10+46.3%+35.1%$2.21B$330.19M-10.94990Positive NewsHigh Trading VolumeHCMHUTCHMED2.294 of 5 stars$12.14-15.6%$19.00+56.5%-18.6%$2.12B$630.20M0.001,988Positive NewsGap DownMIRMMirum Pharmaceuticals3.9566 of 5 stars$41.00-2.5%$58.20+42.0%+61.6%$2.01B$336.89M-20.30140Positive NewsVCELVericel2.417 of 5 stars$39.90-4.8%$62.29+56.1%-13.7%$2.00B$237.22M665.11300News CoveragePositive NewsGap DownHigh Trading VolumeBHCBausch Health Companies4.0027 of 5 stars$5.26-1.4%$7.17+36.4%-47.6%$1.93B$9.63B-43.7919,900Short Interest ↑Positive NewsGap DownBHVNBiohaven3.5014 of 5 stars$17.86-3.9%$62.77+251.4%-58.5%$1.82BN/A-1.91239TARSTarsus Pharmaceuticals2.9585 of 5 stars$47.49+1.0%$63.67+34.1%+40.6%$1.82B$182.95M-12.4650Positive NewsGMTXGemini TherapeuticsN/A$41.22-9.9%N/A+26.5%$1.79BN/A-41.2230Gap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies AMRX Alternatives MLTX Alternatives TWST Alternatives HCM Alternatives MIRM Alternatives VCEL Alternatives BHC Alternatives BHVN Alternatives TARS Alternatives GMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVI) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRVI Stock Free TRVI Stock Alerts